277 related articles for article (PubMed ID: 27009458)
1. Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
Bromberg DJ; Valenzuela M; Nanjappa S; Pabbathi S
Cancer Control; 2016 Jan; 23(1):59-60. PubMed ID: 27009458
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
3. Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ
N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613
[TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
5. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Bell T; Crown JP; Lang I; Bhattacharyya H; Zanotti G; Randolph S; Kim S; Huang X; Huang Bartlett C; Finn RS; Slamon D
Curr Med Res Opin; 2016 May; 32(5):959-65. PubMed ID: 26894413
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Walker AJ; Wedam S; Amiri-Kordestani L; Bloomquist E; Tang S; Sridhara R; Chen W; Palmby TR; Fourie Zirkelbach J; Fu W; Liu Q; Tilley A; Kim G; Kluetz PG; McKee AE; Pazdur R
Clin Cancer Res; 2016 Oct; 22(20):4968-4972. PubMed ID: 27407089
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib: first global approval.
Dhillon S
Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
Hoste G; Punie K; Wildiers H; Beuselinck B; Lefever I; Van Nieuwenhuysen E; Han SN; Berteloot P; Concin N; Salihi R; Vergote I; Neven P
Breast Cancer Res Treat; 2018 Aug; 171(1):131-141. PubMed ID: 29766363
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Kim ES; Scott LJ
Target Oncol; 2017 Jun; 12(3):373-383. PubMed ID: 28488183
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Raphael J; Helou J; Pritchard KI; Naimark DM
Eur J Cancer; 2017 Nov; 85():146-154. PubMed ID: 28930692
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Matter-Walstra K; Ruhstaller T; Klingbiel D; Schwenkglenks M; Dedes KJ
Breast Cancer Res Treat; 2016 Jul; 158(1):51-57. PubMed ID: 27277747
[TBL] [Abstract][Full Text] [Related]
13. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
[TBL] [Abstract][Full Text] [Related]
14. A single institution experience with palbociclib toxicity requiring dose modifications.
Gong J; Cho M; Yu KW; Waisman J; Yuan Y; Mortimer J
Breast Cancer Res Treat; 2018 Apr; 168(2):381-387. PubMed ID: 29218462
[TBL] [Abstract][Full Text] [Related]
15. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
[TBL] [Abstract][Full Text] [Related]
16. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
17. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Beaver JA; Amiri-Kordestani L; Charlab R; Chen W; Palmby T; Tilley A; Zirkelbach JF; Yu J; Liu Q; Zhao L; Crich J; Chen XH; Hughes M; Bloomquist E; Tang S; Sridhara R; Kluetz PG; Kim G; Ibrahim A; Pazdur R; Cortazar P
Clin Cancer Res; 2015 Nov; 21(21):4760-6. PubMed ID: 26324739
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Freedman RA; Tolaney SM
Breast Cancer Res Treat; 2018 Feb; 167(3):607-614. PubMed ID: 29103175
[TBL] [Abstract][Full Text] [Related]
20. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
Battisti NML; Kingston B; King J; Denton A; Waters S; Sita-Lumsden A; Rehman F; Stavraka C; Kristeleit H; Sawyer E; Houghton D; Davidson N; Howell S; Choy J; Harper P; Roylance R; Fharat R; Mohammed K; Ring A; Johnston S
Breast Cancer Res Treat; 2019 Apr; 174(3):731-740. PubMed ID: 30656459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]